Cargando…

Relevance of endoscopic ultrasound in the management of esophagus cancer therapy

INTRODUCTION: The objective of this case series study by retrospective analysis was to determine the relevance of endoscopic ultrasound (EUS) in therapeutic decision esophageal cancer. MATERIAL AND METHODS: Using medical records of the Department of Endoscopy of Santa Casa de São Paulo, we have coll...

Descripción completa

Detalles Bibliográficos
Autores principales: Assef, M., Rossini, L., Araki, O., Nakao, F., Silva, J., Duenas, W., Gagliardi, D., Fabricio, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569914/
https://www.ncbi.nlm.nih.gov/pubmed/26425516
_version_ 1782390127587229696
author Assef, M.
Rossini, L.
Rossini, L.
Araki, O.
Nakao, F.
Silva, J.
Duenas, W.
Gagliardi, D.
Fabricio, V.
author_facet Assef, M.
Rossini, L.
Rossini, L.
Araki, O.
Nakao, F.
Silva, J.
Duenas, W.
Gagliardi, D.
Fabricio, V.
author_sort Assef, M.
collection PubMed
description INTRODUCTION: The objective of this case series study by retrospective analysis was to determine the relevance of endoscopic ultrasound (EUS) in therapeutic decision esophageal cancer. MATERIAL AND METHODS: Using medical records of the Department of Endoscopy of Santa Casa de São Paulo, we have collected data from 16 patients, in 4 years, diagnosed of esophageal cancer, and presented in the form of clinical cases to a specialist surgeon in esophageal cancer and a clinical oncologist, for therapeutic evaluation before and after the outcome of EUS. RESULTS: Both of them choose non-resective and not curative methods (68.8% by surgeon vs. 87.5% oncologist) before EUS. The best treatment by the surgeon was chemotherapy and palliative radiotherapy associated (25%) and palliative endoscopic prostheses (25%), and by the oncologist, neoadjuvant chemotherapy and radiotherapy associated (56.2%). After EUS, the resective surgical treatment was the both choice in only 6.2% of cases, and the rest of 93.8%, non-resective. The surgeon choice was chemotherapy and palliative radiotherapy associated (44%), and oncologist choice was neoadjuvant chemotherapy and radiotherapy associated (44%). Analysis by the Chi-square method, comparing respective versus non-resective treatment, surgeon versus oncologist, with and without the EUS, obtained values of P = 0.39 and P = 0.46, respectively. The comparison between healing and non-healing treatment had the same P value. Regarding the change in behavior (resective vs. non-resective), there was a change of approach by the surgeon in 25% of cases (P = 0.17) and the oncologist moved conduct in 6.25% of cases. Comparing the changing of behavior among experts, the P value was 0.33. Despite evidence of behavior change after the EUS, the statistical point of view, the P value had no significant relevance. The main factor involved is probably due to a reduced number of sample cases. However, this is a pilot study, and is needed other with a larger number of cases. CONCLUSION: The data obtained allow us to conclude that EUS proved to be an important test for the change in staging and therapeutic management of esophageal cancer.
format Online
Article
Text
id pubmed-4569914
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-45699142015-09-30 Relevance of endoscopic ultrasound in the management of esophagus cancer therapy Assef, M. Rossini, L. Rossini, L. Araki, O. Nakao, F. Silva, J. Duenas, W. Gagliardi, D. Fabricio, V. Endosc Ultrasound EURO EUS Meeting INTRODUCTION: The objective of this case series study by retrospective analysis was to determine the relevance of endoscopic ultrasound (EUS) in therapeutic decision esophageal cancer. MATERIAL AND METHODS: Using medical records of the Department of Endoscopy of Santa Casa de São Paulo, we have collected data from 16 patients, in 4 years, diagnosed of esophageal cancer, and presented in the form of clinical cases to a specialist surgeon in esophageal cancer and a clinical oncologist, for therapeutic evaluation before and after the outcome of EUS. RESULTS: Both of them choose non-resective and not curative methods (68.8% by surgeon vs. 87.5% oncologist) before EUS. The best treatment by the surgeon was chemotherapy and palliative radiotherapy associated (25%) and palliative endoscopic prostheses (25%), and by the oncologist, neoadjuvant chemotherapy and radiotherapy associated (56.2%). After EUS, the resective surgical treatment was the both choice in only 6.2% of cases, and the rest of 93.8%, non-resective. The surgeon choice was chemotherapy and palliative radiotherapy associated (44%), and oncologist choice was neoadjuvant chemotherapy and radiotherapy associated (44%). Analysis by the Chi-square method, comparing respective versus non-resective treatment, surgeon versus oncologist, with and without the EUS, obtained values of P = 0.39 and P = 0.46, respectively. The comparison between healing and non-healing treatment had the same P value. Regarding the change in behavior (resective vs. non-resective), there was a change of approach by the surgeon in 25% of cases (P = 0.17) and the oncologist moved conduct in 6.25% of cases. Comparing the changing of behavior among experts, the P value was 0.33. Despite evidence of behavior change after the EUS, the statistical point of view, the P value had no significant relevance. The main factor involved is probably due to a reduced number of sample cases. However, this is a pilot study, and is needed other with a larger number of cases. CONCLUSION: The data obtained allow us to conclude that EUS proved to be an important test for the change in staging and therapeutic management of esophageal cancer. Medknow Publications & Media Pvt Ltd 2014-04 /pmc/articles/PMC4569914/ /pubmed/26425516 Text en Copyright: © Endoscopic Ultrasound http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle EURO EUS Meeting
Assef, M.
Rossini, L.
Rossini, L.
Araki, O.
Nakao, F.
Silva, J.
Duenas, W.
Gagliardi, D.
Fabricio, V.
Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title_full Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title_fullStr Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title_full_unstemmed Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title_short Relevance of endoscopic ultrasound in the management of esophagus cancer therapy
title_sort relevance of endoscopic ultrasound in the management of esophagus cancer therapy
topic EURO EUS Meeting
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569914/
https://www.ncbi.nlm.nih.gov/pubmed/26425516
work_keys_str_mv AT assefm relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT rossinil relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT rossinil relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT arakio relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT nakaof relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT silvaj relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT duenasw relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT gagliardid relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy
AT fabriciov relevanceofendoscopicultrasoundinthemanagementofesophaguscancertherapy